Introduction {#s01}
============

The differentiation propensities of human pluripotent stem cell (hPSC) lines vary from one line to another ([@bib24]; [@bib4]; [@bib8]; [@bib13]). Some cell lines fail to yield terminally differentiated cells at subsequent stages of differentiation ([@bib32]). These limitations in the ability to systematically differentiate hPSC lines into desired lineages substantially restrict their utility for cell replacement therapy and disease modeling, as moving stem cell--based therapies to patients will require the ability to differentiate all cell lines.

Here, we show that PP1, a Src tyrosine kinase inhibitor, regulates the retinoblastoma protein (Rb) and cell cycle of hPSCs, enriches cells in the early G1 phase, and improves their multilineage differentiation potential. Importantly, the PP1 treatment yields high differentiation efficiencies even in cell lines that have low differentiation propensities under control conditions. We demonstrate these effects in both human embryonic and induced pluripotent stem cell (iPSC) lines. Furthermore, we show that Src plays an important regulatory role in this process, as genetic suppression of Src regulates Rb activity and enhances the differentiation potential of hPSCs.

Our focus on PP1 and Src was motivated by the finding that the embryonic cell cycle lengthens to incorporate gap phases as it transitions from a proliferative stage to a stage governed by cell fate decisions ([@bib36]; [@bib17]; [@bib22]; [@bib12]; [@bib10]). One mechanism that plays a critical role in maintaining cell proliferation at the early developmental stages is Src tyrosine kinase signaling ([@bib11]; [@bib28]; [@bib19]). High protein tyrosine kinase activity is required for the early developmental events that occur before cell fate specification ([@bib18]; [@bib21]). Analogous to early development, Src activity is elevated in proliferating PSCs ([@bib1]), potentially preventing the lengthening of the cell cycle for differentiation and cell fate specification. We therefore hypothesized that inhibiting Src activity might regulate the cell cycle and improve the differentiation propensity of hPSCs.

In previous work, we showed that treatment of hPSCs with DMSO improves differentiation propensity after directed differentiation ([@bib8]). The present study provides a new tool to improve differentiation and strengthens the case that manipulating the cell cycle is critical for improving directed differentiation. The mechanistic results presented here indicate that Src plays an important regulatory role in controlling cell fate decisions of hPSCs.

Results {#s02}
=======

PP1 treatment improves the differentiation capacity of hPSCs in a dose-dependent manner {#s03}
---------------------------------------------------------------------------------------

Src-tyrosine kinase signaling regulates cell growth and proliferation of various cell types, including PSCs ([@bib1]), cancer cells ([@bib11]), and normal somatic cells ([@bib26]). In most cell types, Src is negatively regulated (held in an inactive state), but in PSCs and cancer cells, Src activity is elevated ([@bib11]; [@bib1]). PP1 ([Fig. 1 A](#fig1){ref-type="fig"}) has been shown to effectively block Src activity and the proliferation of many types of tumorigenic cells ([@bib15]; [@bib2]). We tested whether inhibition of Src signaling by PP1 treatment affects the differentiation capacity of hPSCs. We focused on the hPSC line HUES6, a cell line with a 24-h doubling time that does not exhibit bias toward any particular lineage and is representative of cell lines with relatively low efficiencies of differentiation ([@bib9]; [@bib24]; [@bib4]). To enhance therapeutic utility, differentiations were performed under low-serum conditions. After a 24-h treatment with PP1 at different doses, HUES6 cells were cultured in differentiation media with Wnt3a and Activin A for 24 h, then assessed for the percentage of cells that differentiated into Brachyury (Brachy)+ cells, a marker for mesendoderm and an early marker for differentiation ([Fig. 1 B](#fig1){ref-type="fig"}).

![**PP1 treatment improves the differentiation capacity of hPSCs in a dose-dependent manner.** (A) Chemical structure of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-d-3,4-pyrimidine (PP1). (B) Schematic of directed differentiation of hPSCs into Brachy+ cells after no treatment (control) or a 24-h PP1 treatment at varying doses. (C--E) Percentages (C) and absolute numbers (D) of control and PP1-treated HUES6 hPSCs differentiating into Brachy+ cells in relation to the total cell numbers (E) in control and PP1-treated cultures. (F) Immunostaining for Oct4, Brachy, and DAPI in control and PP1-treated cultures after directed differentiation. Error bars indicate SEM of three replicates. Bars, 200 µM.](JCB_201502035_Fig1){#fig1}

A 24-h treatment with PP1 increased the percentage as well as the total number of cells that differentiated compared with untreated control cells in a dose-dependent manner ([Fig. 1, C--F](#fig1){ref-type="fig"}). At dosages of 25--50 µM, the percentage of cells differentiating into Brachy+ cells reached nearly 50%, an ∼300-fold enhancement relative to control cells. In all conditions, cells that did not differentiate retained the pluripotency marker Oct4 ([Fig. 1 F](#fig1){ref-type="fig"}). Because a 25-µM PP1 treatment maximizes the percentage and total number of differentiated cells, we used this as an optimal dosage in subsequent analyses. Improvements in differentiation capacity were also observed in other human embryonic and iPSC lines after a 24-h PP1 (25 µM) treatment ([Fig. 2](#fig2){ref-type="fig"}). These improvements were driven by an enhanced competency for differentiation; across all cell lines, the rate of cell death did not differ significantly between the two groups ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp1}; P = 0.3 Annexin+/PI−; P = 0.1 Annexin+/PI+).

![**PP1 treatment improves differentiation capacity across hPSC lines.** (A) Schematic of directed differentiation of hPSCs into Brachy+ cells after no treatment (control) or a 24-h 25 µM PP1 treatment. (B--I) Percentages and absolute numbers of control and PP1-treated hPSCs differentiating into Brachy+ cells in the HUES8 (B and C), HUES49 (D and E), H9 (F and G), and iPSC 11b (H and I) hPSC lines. Error bars indicate SEM of two replicates (HUES49, H9, iPSC11b) or four replicates (HUES8). \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001.](JCB_201502035_Fig2){#fig2}

The change in intercellular morphology with exposure to PP1 is consistent with the effects of Src activity on cell--cell adhesion ([@bib11]; [@bib26]). While elevated Src activity disrupts cell--cell adhesion, inhibition of its activity is associated with improved multicellular interactions ([@bib28]). Cells treated with higher dosages of PP1 aggregate into tight, dense clusters distinct from the spread-out, planar arrangement of control cells and cells treated with low doses of PP1 ([Fig. 1 F](#fig1){ref-type="fig"}).

In addition to dosage, the duration of the PP1 treatment can also regulate the differentiation capacity of hPSCs. Treatment durations that were shorter than the cell line's doubling time induced only a 2--5% differentiation rate (unpublished data).

Among the inhibitors tested, PP1 proved to be the most effective in enhancing differentiation potential. Consistent with prior reports, treatment of hPSCs with other inhibitors to perturb various cell cycle--related kinase signaling pathways had a minimal or moderate effect on improving differentiation potential ([@bib31]; [@bib23]; [@bib20]). Treatment with a Cdk2 inhibitor at 5--10 µM induced ∼20% of the cells to differentiate into Brachy+ cells but was associated with a substantial degree of cell loss at higher doses ([Fig. S2, A--I](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp2}).

PP1 treatment regulates the cell cycle and activity of Rb in hPSCs {#s04}
------------------------------------------------------------------

Given that the PP1 treatment effectively enhances differentiation potential at the 24 h time point, we treated hPSCs with 25 µM PP1 for 24 h and investigated the effects on the cell cycle. Cell cycle analysis by flow cytometry showed that the PP1 treatment changes the distribution of hPSCs in the G1, S, and G2/M phases of the cell cycle, increasing the proportion of cells in G1 and decreasing the number of cells in the S and G2/M phases. These effects were consistently observed in several human embryonic and iPSC lines ([Figs. 3](#fig3){ref-type="fig"}, [4 A](#fig4){ref-type="fig"}, and [S3](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp3}). Further investigation of the HUES6 cell line showed that a 24-h treatment with 25 µM PP1 nearly doubles the percentage of cells in G1 phase (∼70%) compared with controls (∼35%; [Fig. 4 B](#fig4){ref-type="fig"}). The proportion of cells in the S and G2/M phases is concomitantly reduced by at least twofold after the PP1 treatment ([Fig. 4 B](#fig4){ref-type="fig"}). A significant shift toward G1 was observed across all cell lines ([Fig. 3](#fig3){ref-type="fig"} and Fig. S3; P \< 0.002).

![**PP1 treatment enriches cells in G1 across hPSC lines.** Distribution of hPSCs in the G1, S, and G2/M phases of the cell cycle after no treatment (control) or a 24-h 25 µM PP1 treatment in the HUES8 (A), HUES49 (B), H9 (C), and iPSC 11b (D) hPSC lines. (E) Mean percentage of hPSCs across all cell lines in the G1, S, and G2/M phases of the cell cycle after no treatment (control) or a 24-h 25 µM PP1 treatment.](JCB_201502035_Fig3){#fig3}

![**PP1 treatment regulates the cell cycle and enhances the activity of Rb in hPSCs.** (A and B) Distribution (A) and percentage (B) of HUES6 hPSCs in the G1, S, and G2/M phases of the cell cycle after no treatment (Control) or a 24-h 25 µM PP1 treatment. (C) Immunostaining for the active hypophosphorylated Rb (red) and inactive phosphorylated pRb780 (green) in control and PP1-treated hPSCs. Bar, 200 µM. (D and E) Percentage of hPSCs expressing hypophosphorylated Rb (D) and hyperphosphorylated Rb (E; pRb780) after no treatment (Control) or a 24-h 25 µM PP1 treatment. (F and G) Flow cytometry analysis of the percentage of hPSCs expressing the retinoblastoma-associated protein 46/48 (RbAP46/48) after no treatment (Control) or a 24-h 25 µM PP1 treatment. (H) Relative expression levels of cell cycle--regulated genes in PP1-treated hPSCs compared with untreated controls. Error bars indicate SEM of 2--3 replicates. \*, P ≤ 0.05; \*\*, P ≤ 0.01.](JCB_201502035_Fig4){#fig4}

Rb predominantly remains in an inactive hyperphosphorylated state throughout the cell cycle of human and mouse PSCs. While phosphorylated Rb promotes cell division, the accumulation of hypophosphorylated Rb (active Rb) is associated with an enrichment of cells in the early G1 phase of the cell cycle and an improved capacity for differentiation ([@bib6]; [@bib7]; [@bib23]). We assessed the phosphorylation status of Rb in control and 25 µM PP1--treated hPSCs. After a 24-h PP1 treatment, the percentage of hPSCs expressing hypophosphorylated Rb increased by \>60-fold from 0.3% to 20% ([Fig. 4, C and D](#fig4){ref-type="fig"}). Phosphorylation of Rb occurs at 16 distinct sites ([@bib16]). Assessment of the inactive phosphorylated status of Rb at one of these sites (serine 780) showed that PP1 treatment leads to a twofold reduction in the percentage of cells expressing pRb780 ([Fig. 4, C and E](#fig4){ref-type="fig"}). The phosphorylation of Rb at serine 780 was also differentially regulated by other cell cycle inhibitors (Fig. S2 J).

In its hypophosphorylated state, Rb plays a critical role in growth suppression. In coordination with Rb, the retinoblastoma-associated protein 46/48 (RbAP46/48; a histone chaperone protein) regulates the cell cycle by aiding in the transcriptional repression of Rb-related target genes, particularly genes involved in the G1 to S phase transition ([@bib16]; [@bib34]). We assessed the fraction of cells expressing the cofactor RbAP46/48 in control and PP1-treated hPSCs. Flow cytometry analysis showed that the percentage of hPSCs expressing RbAP46/48 nearly doubles between control and PP1-treated cells ([Fig. 4, F and G](#fig4){ref-type="fig"}). Furthermore, treatment with 25 µM PP1 for 24 h also regulated the expression of many genes associated with cell cycle control. The expression of genes promoting cell division, including *Cyclin* *A1*, *Cdk2*, and *Cdc6*, were significantly reduced in PP1-treated hPSCs relative to control cells ([Fig. 4 H](#fig4){ref-type="fig"}). Expression of *p27*, a cell cycle inhibitor that promotes growth arrest in G1 ([@bib35]), was significantly increased in PP1-treated hPSCs compared with control cells ([Fig. 4 H](#fig4){ref-type="fig"}). No significant difference in expression levels was observed for *Cyclin A2*, *Cyclin D1*, *Cyclin E1*, *E2f1*, and *p21* between control and PP1-treated hPSCs ([Fig. 4 H](#fig4){ref-type="fig"}). Together, these results show that PP1 treatment of hPSCs promotes growth inhibition and an accumulation of cells in the G1 phase by regulating genes involved in the G1 to S phase transition. The enhanced hypophosphorylated state of Rb increases the proportion of cells in the early G1 phase and more generally indicates an increased presence of early G1 in the hPSC cycle after PP1 treatment.

Genetic suppression of Src regulates Rb activity and improves the differentiation capacity of hPSCs across all germ layers {#s05}
--------------------------------------------------------------------------------------------------------------------------

Given that PP1 is a potent Src inhibitor ([@bib15]; [@bib2]), we assessed whether treatment of hPSCs with PP1 reduced protein levels of Src. Western blot analysis using two different Src specific antibodies showed that PP1 treatment does indeed suppress Src levels ([Fig. 5 A](#fig5){ref-type="fig"}). To investigate whether suppression of Src mimics the effects of PP1 on hPSCs, we next genetically suppressed Src in hPSCs using siRNA. siRNA-mediated knockdown of Src suppressed both the gene expression ([Fig. 5 B](#fig5){ref-type="fig"}) and protein ([Fig. 5 C](#fig5){ref-type="fig"}) levels of Src in hPSCs. Similar to PP1, Src knockdown also enhanced the activity of Rb by substantially reducing the levels of the phosphorylated and hyperphosphorylated forms of the Rb protein (ppRb) and increasing levels of the hypo- or underphosphorylated forms of Rb ([Fig. 5 C](#fig5){ref-type="fig"}). Together with PP1, these results provide further support that inhibition of Src increases the proportion of hPSCs in the early G1 phase of the cell cycle.

![**Genetic suppression of Src regulates the activity of Rb and improves the differentiation capacity of hPSCs across all germ layers.** (A) Western blot with Src-specific antibodies shows the levels of the Src protein after PP1 treatment of hPSCs. (B) Relative expression level of the Src gene in hPSCs transfected with Src siRNA compared with hPSCs transfected with nontargeting control siRNA. (C) Western blot with Src-specific antibodies shows the levels of the Src protein in hPSCs transfected with Src siRNA; phospho-specific antibodies show the levels of the indicated phosphorylated forms of Rb after transfection with Src siRNA. ppRb, hyperphosphorylated Rb. (D) Schematic of directed differentiation of hPSCs into Sox1+ ectodermal, Brachy+ mesodermal, or Sox17+ endodermal cells after transfection of hPSCs with control siRNA or Src siRNA. (E) Immunostaining for the indicated differentiation markers after directed differentiation in control and Src siRNA--transfected cultures. Bar, 200 µM. (F) Percentages of cells expressing the indicated differentiation markers in control and Src siRNA--transfected cultures. Error bars indicate SEM of 2--3 replicates. \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001.](JCB_201502035_Fig5){#fig5}

Prior literature has shown that cells have an enhanced capacity to respond to extracellular signals in the G1 phase ([@bib27]). To investigate whether these effects regulate the differentiation propensity of hPSCs, we next assessed whether genetic suppression of Src improves the differentiation potential of hPSCs across all germ layers. After Src knockdown of hPSCs with siRNA, we subsequently induced differentiation into each of the germ layers using three different directed differentiation protocols ([@bib8]; [Fig. 5 D](#fig5){ref-type="fig"}). The percentage of cells becoming Sox1+, Brachy+, and Sox17+ cells was quantified to assess multilineage differentiation potential into the ectodermal, mesodermal, and endodermal germ layers, respectively ([Fig. 5 D](#fig5){ref-type="fig"}). Transfection of hPSCs with Src siRNA before directed differentiation significantly increased the number and percentage of differentiated cells across all three germ layers ([Fig. 5, E and F](#fig5){ref-type="fig"}). After Src knockdown, the percentage of hPSCs that differentiated into each germ layer was enhanced by ∼2--10-fold ([Fig. 5 F](#fig5){ref-type="fig"}). At the time points assessed, differentiation rates of ∼50% were observed across all the germ layers after Src knockdown ([Fig. 5 F](#fig5){ref-type="fig"}). While Src knockdown promoted aggregation of cells initially, the cells spread out more rapidly after differentiation compared with the PP1 treatment. The suppression of the protein expression of Src was also reduced to a greater degree in PP1-treated cultures compared with genetic suppression of Src, potentially due to variations in potency and/or technical limitations of using siRNA ([Fig. 5, A and C](#fig5){ref-type="fig"}).

PP1 treatment improves the differentiation capacity of hPSCs across all germ layers {#s06}
-----------------------------------------------------------------------------------

Similar to Src knockdown, we next tested whether the PP1 treatment improves the differentiation potential of hPSCs across germ layers. We treated HUES6 hPSCs with 25 µM PP1 for 24 h and subsequently induced differentiation into each of the germ layers ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp4}). The percentage of cells becoming Pax6+, Brachy+, and Sox17+ cells was quantified to assess multilineage differentiation potential into the ectodermal, mesodermal, and endodermal germ layers, respectively (Fig. S4 A). Treatment of hPSCs with 25 µM PP1 for 24 h before directed differentiation significantly increased the number and percentage of differentiated cells across all three germ layers (Fig. S4, B and C). No significant differences in total cell number were observed for differentiations toward the ectodermal and endodermal germ layers. A 1-d differentiation toward the mesodermal germ layer resulted in a reduction in total cell number after the PP1 treatment. After PP1 treatment, the percentage of hPSCs that differentiated into each germ layer was enhanced by ∼10-fold for ectodermal differentiation, 60-fold for mesodermal differentiation, and 2.5-fold for endodermal differentiation (Fig. S4 C). At the time points assessed, differentiation rates of 40--75% were observed across all the germ layers after the PP1 treatment, roughly comparable to the differentiation rates observed for genetic suppression of Src ([Fig. 5](#fig5){ref-type="fig"}). Differences in these rates between the PP1 treatment and genetic suppression of Src could be due to variations in the potency of the treatments.

To further evaluate how well stem cells differentiate into the three germ layers after the PP1 treatment, we used the highly quantitative PCR (qPCR)-based Scorecard assay as an assessment of lineage specification ([@bib4]). Three published directed differentiation protocols were used to differentiate hPSCs into representative populations of the ectodermal (dEC), mesodermal (dME), and endodermal (dEN) germ layers ([@bib14]; [Fig. 6 A](#fig6){ref-type="fig"}). The expression levels of a panel of genes specific to pluripotent stem cells and the three germ layers were measured in control and PP1-treated hPSCs and differentiated cultures. For most germ layer markers, higher expression levels were observed in PP1-treated differentiated cells compared with controls ([Fig. 6 B](#fig6){ref-type="fig"}). The mean expression across all ectodermal, mesodermal, and endodermal markers on the panel was also significantly higher in PP1-treated differentiated cells relative to controls ([Fig. 6 B](#fig6){ref-type="fig"}, right bars). These differences were generally not present in PP1-treated and control hPSCs before directed differentiation (Fig. S4 D). In comparison to a reference set of 14 other pluripotent stem cell lines, the PP1-treated differentiated cells had a higher germ layer differentiation potential than control samples (Fig. S4, E and F) and often had higher potential than other cell lines in the reference set.

![**PP1 treatment improves the specificity of differentiation of hPSCs.** (A) Schematic of directed differentiation of HUES6 hPSCs into ectoderm (dEC, blue), mesoderm (dME, green), and endoderm (dEN, yellow) populations. (B) Difference in mean expression between PP1-treated and control samples, −∂CT = −(CT~PP1~ − CT~CONTROL~), for selected ectoderm (left), mesoderm (center), and endoderm (right) marker genes after directed differentiation into the three germ layers. All markers with −∂CT ≥ 1.9 or ≤ −1.9 are displayed, where −∂CT = 2 represents a fourfold increase in expression for PP1-treated versus control samples. The mean difference in expression for all ectoderm, mesoderm, and endoderm markers on the Scorecard panel (Life Technologies) is displayed as the rightmost bar. Error bars indicate standard deviation in difference in expression of two replicates. (C) Schematic of stepwise differentiation into pancreatic progenitor (PP1; Pdx1+) cells following a 15-d directed differentiation protocol after no treatment (control) or a 24-h 25 µM PP1 treatment. (D) Immunostaining for Pdx1 in control and PP1-treated cultures after directed differentiation. Bar, 200 µM. (E) Percentage of cells differentiating into Pdx1+ pancreatic progenitor cells in control and PP1-treated cultures. (F) Total cell numbers in control and PP1-treated cultures through the three stages of directed differentiation. Error bars indicate SEM of 4--6 replicates. \*\*\*, P ≤ 0.001.](JCB_201502035_Fig6){#fig6}

These results show that the PP1 treatment improves lineage specification after directed differentiation by enhancing the expression of genes relevant for a given lineage. Together, these analyses show that the PP1 treatment improves the capacity for differentiation using six different induction protocols.

Improvements in lineage specification would predict that the PP1 effects should persist to improve differentiation at subsequent stages of differentiation. To evaluate the long-term effects of PP1, hPSCs were differentiated through a 15-d directed differentiation protocol into Pdx1+ pancreatic progenitor cells after the initial 24-h 25 µM PP1 treatment ([Fig. 6 C](#fig6){ref-type="fig"}). The PP1 treatment of hPSCs increased the number of Pdx1+ cells by threefold, inducing a 70% differentiation rate ([Fig. 6, D and E](#fig6){ref-type="fig"}). The PP1-treated cells also continued to expand throughout the stages of the directed differentiation protocol ([Fig. 6 F](#fig6){ref-type="fig"}). Further differentiation of the PP1-treated hPSCs toward terminally differentiated cells of the pancreatic lineage ([Fig. S5 A](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp5}) promoted differentiation into Nkx6.1+ and Ngn3+ endocrine cells as well as hormone-expressing C-peptide+ cells (Fig. S5 B). Thus, the increased differentiation efficiency after PP1 treatment is sustained throughout subsequent stages of differentiation and shows that the PP1 treatment is capable of driving hPSCs past the initial germ layers toward later stages of development.

In prior work, we showed that pretreatment with DMSO at a concentration of 1--2% could significantly improve the differentiation propensities of hPSCs ([@bib8]). We tested whether combining PP1 and DMSO could have beneficial effects on hPSC differentiation. While combining the two treatments (25 µM PP1 with 2% DMSO) simultaneously compromised cell survival (unpublished data), sequential treatment with a lower concentration of DMSO (0.5%) had positive effects. After a 24-h treatment with 25 µM PP1, hPSCs were treated with 0.5% DMSO for 24 h and then cultured in differentiation media with Wnt3a and Activin A for 24 h (Fig. S5 C). This combined treatment increased the percentage and absolute number of Brachy+ cells relative to cultures treated with PP1 alone in the HUES 6 line ([Fig. 1](#fig1){ref-type="fig"} and Fig. S5, D--F). The combined treatment increased the absolute yield of differentiated cells in other cell lines as well (Fig. S5 G). These findings indicate that optimizing the concentrations and timing of the DMSO and PP1 treatments could provide further benefits for directed differentiation. Using different doses of these two treatments at various stages of directed differentiation could also improve long-term differentiation potential and should be further explored.

Discussion {#s07}
==========

In summary, the results show that a potent Src inhibitor, PP1, regulates the cell cycle and differentiation capacity of both human embryonic and iPSCs. A 24-h treatment with PP1 modulates the expression of genes involved in the G1 to S phase transition, enhances Rb activity, and increases the percent of cells in the early G1 phase of the cell cycle. After these effects, hPSCs respond more efficiently and effectively to various directed differentiation protocols, leading to improvements in differentiation potentials across all germ layers. Genetic suppression of Src in hPSCs similarly activates Rb and improves differentiation capacity, suggesting an important role for Src in controlling proliferation and differentiation. These early manipulations of the starting state of hPSCs increase the output and specificity of differentiated cells at subsequent stages. The PP1 treatment enhances the yield of differentiated cells to 80% even in cell lines that would otherwise have low differentiation propensities. In cases where efficiencies are already high under control conditions, PP1 has no adverse effects. Thus, the effects are durable in that they extend beyond the initial germ layer specification.

Our findings on the importance of the cell cycle mirror results in the literature on embryogenesis. In early development as well as in pluripotent stem cells, a truncated cell cycle initially supports the amplification of cells ([@bib31]; [@bib23]). However, the cell cycle then lengthens as development progresses to incorporate gap phases and give cells the opportunity to become more specialized ([@bib36]; [@bib17]; [@bib22]; [@bib12]; [@bib10]). Similarly, lengthening the truncated cell cycle of pluripotent stem cells through suppression of Src or small molecules such as PP1 may help direct their differentiation into specialized cell types.

Few factors have been identified to date that effectively regulate the pluripotent cell cycle and directed differentiation ([@bib31]; [@bib23]; [@bib37]; [@bib8]; [@bib20]). PP1 has proven to be a potent tool to regulate the pluripotent G1 phase, as it enhances the hypophosphorylated state of Rb and enriches cells in the early G1 phase before directed differentiation. Our findings also support recent work suggesting that the G1 phase of the cell cycle may play an important role in enhancing the differentiation of hPSCs ([@bib29]; [@bib25]; [@bib30]). Given its role in regulating Rb and the cell cycle, PP1 could also be a useful tool in controlling the tumorigenicity of pluripotent stem cells and their differentiated progeny to enhance their therapeutic utility ([@bib3]).

The robust impacts of the PP1 treatment and genetic suppression of Src on hPSCs are consistent with prior work showing the importance of Src tyrosine kinase activity in regulating cell proliferation in early development ([@bib36]; [@bib12]). In addition, with the evolution of multicellular organisms, a negative regulation of Src was acquired that proved to be critical for interactions and communications between cells ([@bib28]). Src inhibition may similarly play an important regulatory role as a single cell undergoes cell division into a multicellular organism in early development.

More broadly, this study shows that the PP1 treatment alters the "starting state" of hPSCs to be more amenable to directed differentiation. Manipulating this starting state, whether through PP1, direct inhibition of Src, or other tools, increases the utility of pluripotent stem cells. Studying how this state relates to the recently established primitive "reset" state of hPSCs ([@bib33]) could provide further mechanistic insights into how various pluripotent states control cell fate decisions and the developmental potential of pluripotent stem cells.

Materials and methods {#s08}
=====================

hPSC maintenance conditions {#s09}
---------------------------

All hPSC cultures were maintained at 37°C, 5% CO~2~ and grown on a monolayer of irradiated CF1 mouse embryonic fibroblasts (MEFs; GlobalStem) in hPSC medium consisting of KO-DMEM (Invitrogen), 10% KOSR (Invitrogen), 1% GlutaMAX, nonessential amino acids, penicillin/streptomycin, and 0.1% β-mercaptoethanol supplemented with 10 ng/ml bFGF (Invitrogen). Medium was changed every 24 h, and lines were passaged using TrypLE (Invitrogen). Before differentiation experiments, cells were expanded for at least two passages on Matrigel (BD) in mTeSR (STEMCELL Technologies) with 10 µM of ROCK inhibitor Y-27632 (Abcam).

The HUES cell lines (HUES6, HUES8, HUES49, and H9; [@bib9]; [@bib24]) and the iPSC line (iPSC11b; [@bib5]) were used in this study.

### siRNA transfection {#s10}

Src siRNA (s13414, Life Technologies; Chr. 20: 35973088--36033821) and nontargeting control siRNA (4390843; Life Technologies) were transfected into hPSCs plated onto Matrigel-coated plates at 70% confluence. Cells were transfected with either control siRNA (50 pmol) or Src siRNA (50 pmol) using Lipofectamine RNAimax transfection reagent (Invitrogen), according to the manufacturer's instructions. Cells were subsequently either differentiated or collected for analysis 24 h after transfection.

Differentiation protocols {#s11}
-------------------------

For all differentiation studies, hPSCs were plated onto wells coated with growth factor--reduced Matrigel (BD) in mTeSR with 10 µM ROCK inhibitor Y-27632. Cells were plated at a density of 1--2 million per well of a six-well plate or 100,000--200,000 per well of a 96-well plate. 24 h before the onset of differentiation, cells were cultured in mTeSR with inhibitor treatment. Inhibitor medium was removed after 24 h and replaced with differentiation-inducing media at the start of each differentiation, with replacement of medium every day in all protocols.

Treatments in this study include PP1 (Thermo Fisher Scientific), PP2 (Tocris Bioscience), 1-Naphthyl PP1 (Tocris Bioscience), Saracatinib (Thermo Fisher Scientific), Bosutinib (Sigma-Aldrich), K252a (Sigma-Aldrich), *N*-\[(2*R*)-2,3-Dihydroxypropoxy\]-3,4-difluoro-2-\[(2-fluoro-4-iodophenyl)amino\]-benzamide (Stemgent), Roscovitine (Sigma-Aldrich), CDK2 inhibitor (EMD Millipore), and Palbociclib HCl (Selleck Chemicals) at dosages of 1 µM, 5 µM, 10 µM, 25 µM, 40 µM, and 50 µM for 24 h.

To induce differentiation into the ectodermal, mesodermal, and endodermal germ layers and pancreatic endocrine lineage, cells were directly differentiated as follows.

### Ectoderm {#s12}

Cells were cultured in KO-DMEM (Invitrogen) medium containing 10% knockout serum replacement (Invitrogen) and supplemented with Noggin (500 ng/ml; R&D Systems) and 4-\[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl\]benzamide (10 µM; Tocris) for 3--4 d.

### Mesoderm {#s13}

Cells were cultured in Advanced RPMI 1640 (reduced serum; Invitrogen) or RPMI 1640 medium (Invitrogen) supplemented with human recombinant AA (100 ng/ml) + Wnt3a (20 ng/ml; R&D Systems) for 1 d.

### Endoderm {#s14}

Cells were cultured in MCDB-131 medium (Invitrogen) supplemented with NaHCO~3~ (2.5 g/liter), 1% GlutaMAX, glucose (5.5 mM), 0.1% FAF-BSA (Proliant/Lampire), and ITS:X (1:50,000; Invitrogen), and treated with Wnt3a (20 ng/ml) + AA (100 ng/ml) for 1 d and then AA (100 ng/ml) for 3 d.

### Pancreatic endocrine differentiation {#s15}

Cells were cultured in MCDB-131 medium supplemented with NaHCO~3~ (2.5 g/liter), 1% GlutaMAX, glucose (5.5 mM), 0.1% FAF-BSA, and ITS:X (1:50,000), and were treated with Wnt3a (20 ng/ml) + AA (100 ng/ml) for 1 d, AA (100 ng/ml) for 3 d, and FGF7 (50 ng/ml; PeproTech) for 2 d. For further endocrine differentiation, cells were cultured in MCDB-131 medium supplemented with NaHCO~3~ (2.5 g/liter), 1% GlutaMAX, glucose (8 mM), 2% FAF-BSA, and ITS:X (1:200), and treated for 4 d with FGF7 (50 ng/ml) + noggin (100 ng/ml) + retinoic acid (2 µM; Sigma-Aldrich) + SANT-1 (0.25 µM; Sigma-Aldrich) + AA (20 ng/ml); for 3 d with SANT-1 (0.25 µM) + PdBu (200 nM; EMD) + noggin (100 ng/ml); and for 4--6 d with noggin (100 ng/ml) + Alk5 inhibitor (1 µM; Axxora).

Directed differentiations for the scorecard analyses were performed using the following previously published protocols ([@bib14]).

### Ectoderm {#s16}

Ectoderm differentiation was induced using A83-01 (2 µm; Tocris Bioscience), PNU 74654 (2 µm; Tocris Bioscience), Dorsomorphin (2 µm; Tocris Bioscience), and DMEM/F12 (Life Technologies) containing 15% knockout serum replacement (Life Technologies) for 4 d.

### Mesoderm {#s17}

Mesoderm differentiation was induced in DMEM/F12 (Life Technologies) and 0.5% FBS (HyClone; GE Healthcare), with Activin A (100 ng/ml; R&D Systems) for 1 d, and subsequently induced with BMP4 (100 ng/ml; R&D Systems), VEGF (100 ng/ml; R&D Systems), and FGF2 (20 ng/ml; Millipore) for 3 d.

### Endoderm {#s18}

Endoderm differentiation was induced in Advanced RPMI (Invitrogen) and 0.5% FBS (HyClone), with Activin A (100 ng/ml; R&D Systems) and LiCl (2 µg/ml; R&D Systems) for 4 d.

Immunocytochemistry and quantification {#s19}
--------------------------------------

Cells were rinsed in PBS and fixed in 4% PFA (Sigma-Aldrich) for 30 min. After the rinses, cells were blocked for 1 h at room temperature in 5% donkey serum (Jackson ImmunoResearch Laboratories, Inc.) and 0.3% Triton X-100 in PBS. All primary antibody incubations were done overnight at 4°C in blocking solution at a 1:500 dilution unless otherwise noted. Primary antibodies used in this study were: Oct4 (mouse; R&D Systems), Sox1 (goat; R&D Systems), Pax6 (rabbit; Covance), Brachyury (goat; R&D Systems), Sox17 (goat; R&D Systems), Pdx1 (goat; R&D Systems), Nkx6.1 (mouse; University of Iowa, Developmental Hybridoma Bank), Ngn3 (sheep; R&D Systems), C-peptide (rat; Developmental Studies Hybridoma Bank), pRb 780 (1:350; Rb phosphorylation at Ser780; rabbit; Cell Signaling Technology), and underphosphorylated Rb (1:100; mouse; BD). Cells were rinsed the next day, followed by secondary antibody incubation for 1 h at room temperature at a 1:500 dilution. Secondary antibodies (Invitrogen) conjugated to Alexa Fluor 488 or 594 were used to visualize primary antibodies. After PBS rinses, all nuclei were visualized by staining with Hoechst 33342 (1:1,000; Invitrogen).

### Image acquisition and quantification {#s20}

Immunofluorescent images were taken using a microscope (Observer.D1; Carl Zeiss) using an LD A-Plan 10×/0.25 NA Ph1 M27 objective lens with the DAPI, GFP, or Texas red fluorochromes. Cells were imaged in PBS at room temperature, and images were acquired using the microscopy camera Axiom 503 mono(D) with the acquisition software AxioVision Rel 4.7 (Carl Zeiss). For quantification analyses, 30 10× fields per well were acquired and quantified using a high-content screening system (ArrayScan VTI; Cellomics Technology). Cells labeled by antibody staining and total cell number (based on DAPI nuclei staining) were quantified to obtain percentages of target cell types.

Flow cytometry {#s21}
--------------

For intracellular antibody staining, cells were fixed in 4% PFA for 20 min at 4°C followed by two PBS washes. Cells were resuspended in blocking solution consisting of 5% donkey serum and 0.3% Triton X-100 in PBS. Cells were then incubated for 30 min at 4°C with primary antibody RbAP46/48 (1:500; rabbit; Active Motif North America) or Ki67 (1:500; rabbit; Abcam) and washed twice in PBS. Last, cells were incubated with secondary antibody donkey anti--rabbit Alexa Fluor 594 (1:500; Invitrogen) for 30 min at 4°C and washed twice before assessment on a flow cytometer (LSRII FACS; BD) and analysis using the FlowJo software.

Annexin V--propidium iodide staining {#s22}
------------------------------------

Cells were harvested with TrypLE Express (Invitrogen), washed with cold PBS, and resuspended with annexin-binding buffer (50 mM Hepes, 700 mM NaCl, and 12.5 mM CaCl~2~, pH 7.4) to a final concentration of 10^6^ cells/ml. 5 µl of Annexin V Alexa Fluor 488 conjugate (Molecular Probes) and 1 µl of 100 µg/ml propidium iodide (Molecular Probes) were added per 100 µl of cell suspension. After 15 min of incubation at room temperature, 400 µl of annexin-binding buffer was added per 100 µl of cell suspension. Samples were mixed gently and left on ice until analysis. Cells were assessed with a flow cytometer (LSRII FACS; BD) and analyzed using FlowJo software.

Western blot analysis {#s23}
---------------------

Cells were lysed using the RIPA lysis buffer (Santa Cruz Biotechnology, Inc.). Proteins were separated by 7.5% SDS-PAGE (Bio-Rad Laboratories) and transferred to nitrocellulose membranes (Bio-Rad Laboratories). The membranes were blocked in 3% BSA in 0.1% Tween 20 TBS for 1 h at room temperature and then incubated with the following primary antibodies overnight at 4°C: Src (47405; 1:1,000; rabbit; Abcam), Src (16885; 1:1,000; mouse; Abcam), ppRb (G3-245; 1:1,000; mouse; BD), underphosphorylated Rb (G99-549; 1:1,000; mouse; BD), or GAPDH (MAB374; 1:1,000; mouse; Millipore) as the loading control. After washing, the membranes were incubated with secondary antibodies for 1 h at room temperature: anti--mouse HRP (1:3,000; Cell Signaling Technology) or anti--rabbit HRP (1:5,000; Cell Signaling Technology), and then incubated in chemiluminescent HRP substrate (Millipore) for signal detection and development.

RNA isolation and gene expression analyses by real-time PCR {#s24}
-----------------------------------------------------------

Total RNAs were isolated from purified cells of untreated and PP1-treated hPSCs using the RNeasy mini kit (QIAGEN) and reverse transcribed using Superscript III RT (Invitrogen), according to the manufacturer's instructions. Real-time qPCR reactions were analyzed with a Mastercycler realplex 4 Sequence Detector (Eppendorf) via SYBR green (QuantitectTM SYBR Green PCR kit; QIAGEN). The relative gene expression level of each sample was expressed as a relative quantitation (RQ) value determined by the 2 − ddCT method that represents the fold change in gene expression normalized to the housekeeping gene, GAPDH. The relative gene expression level of each sample was also compared with an internal control, i.e., untreated hPSCs. Complementary DNA PCR primer sequences are shown in [Table S1](http://www.jcb.org/cgi/content/full/jcb.201502035/DC1){#supp6}.

qPCR and Scorecard analysis {#s25}
---------------------------

Total RNA was extracted from frozen cell pellets using Ambion Pure Link RNA Mini kit (Life Technologies). Eight cDNA reactions were set up from 1 µg of total RNA per sample using a High-Capacity cDNA RT kit (Life Technologies). qPCR was performed on 384-well TaqMan hPSC Scorecard plates using Viia7 RUO software and a ViiA7 instrument (Applied Biosystems). Data were normalized to the mean expression level of five control genes that are highly invariant in expression during directed differentiation. Differentiation potential was calculated ([@bib4]) for four gene classes (EC, ectoderm; ME, mesoderm; EN, endoderm; PP, pluripotent).

Cell cycle analysis {#s26}
-------------------

Cells were trypsinized and fixed in 4% PFA for 20 min on ice and stained with Hoechst 33342 (5 µg/ml; Invitrogen) in PBS for 30 min. Equal numbers of cells were assessed for each cell line on a flow cytometer (LSRII FACS; BD) and analyzed using FlowJo software.

Statistical analysis {#s27}
--------------------

For statistical comparisons, mean values of two or more independent experiments were subjected to unpaired two-tailed Student's *t* tests. P-values ≤0.05 were considered significant.

Online supplemental material {#s28}
----------------------------

Fig. S1 shows cell viability after the PP1 treatment. Fig. S2 shows how various cell cycle inhibitors regulate the differentiation potential of hPSCs. Fig. S3 shows the cell cycle profiles of several cell lines after the PP1 treatment. Fig. S4 shows how PP1 enhances the differentiation potential across all germ layers using various directed differentiation protocols. Fig. S5 shows that the initial PP1 treatment has positive impacts on terminal differentiation and provides benefits on differentiation capacity when combined with a DMSO treatment. Table S1 includes primer sequences used in the study. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201502035/DC1>.
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